AZA-001-301

An 18-month, multicentre, phase 3, double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick disease type C and in late-infantile and juvenile forms of GM1 or GM2 gangliosidosis.